Stanford researchers have developed a new AI tool called SEQUOIA that could replace expensive gene tests for cancer patients. This tool uses standard images of tumor biopsies to predict the activity of thousands of genes, eliminating the need for complex and costly genetic sequencing.
Traditionally, doctors identify gene activity in cancer cells through genetic sequencing, which can take weeks and cost thousands of dollars. SEQUOIA, however, uses AI to analyze biopsy images and determine which genes are active. It can even predict patient outcomes and identify gene patterns that affect cancer growth and treatment responses.
Key Highlights:
- Speed and Cost Savings: SEQUOIA can quickly provide important gene information, helping doctors make faster treatment decisions while reducing healthcare costs.
- Wide Applications: Initially tested on over 7,000 tumor samples from different cancer types, SEQUOIA has shown over 80% accuracy for some cancers.
- Breast Cancer Case Study: SEQUOIA accurately predicted breast cancer risk scores, similar to existing tests like MammaPrint, but without expensive gene sequencing.
The AI model is still being tested and needs FDA approval, but it holds promise for use in clinical settings. In the future, SEQUOIA could help doctors treat various cancers without relying on expensive tests, making cancer care more accessible.
Source: scitechdaily
